This company has been marked as potentially delisted and may not be actively trading. IMMURON (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. SCLX, GRCE, STTK, ANVS, PLUR, MDCX, PEPG, AKTX, XCUR, and RADXShould you be buying IMMURON stock or one of its competitors? The main competitors of IMMURON include Scilex (SCLX), Grace Therapeutics (GRCE), Shattuck Labs (STTK), Annovis Bio (ANVS), Pluri (PLUR), Medicus Pharma (MDCX), PepGen (PEPG), Akari Therapeutics (AKTX), Exicure (XCUR), and Radiopharm Theranostics (RADX). These companies are all part of the "medical" sector. IMMURON vs. Its Competitors Scilex Grace Therapeutics Shattuck Labs Annovis Bio Pluri Medicus Pharma PepGen Akari Therapeutics Exicure Radiopharm Theranostics IMMURON (NASDAQ:IMRN) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals and insiders hold more shares of IMRN or SCLX? 0.1% of IMMURON shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 7.0% of IMMURON shares are held by insiders. Comparatively, 7.9% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, IMRN or SCLX? IMMURON has higher earnings, but lower revenue than Scilex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMMURON$3.21M3.30-$4.55MN/AN/AScilex$56.59M0.74-$72.81M-$29.02-0.21 Do analysts prefer IMRN or SCLX? IMMURON presently has a consensus price target of $5.00, indicating a potential upside of 176.24%. Scilex has a consensus price target of $455.00, indicating a potential upside of 7,483.33%. Given Scilex's higher possible upside, analysts clearly believe Scilex is more favorable than IMMURON.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMMURON 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, IMRN or SCLX? IMMURON has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Does the media favor IMRN or SCLX? In the previous week, Scilex had 1 more articles in the media than IMMURON. MarketBeat recorded 1 mentions for Scilex and 0 mentions for IMMURON. IMMURON's average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score. Company Overall Sentiment IMMURON Neutral Scilex Neutral Is IMRN or SCLX more profitable? IMMURON has a net margin of 0.00% compared to Scilex's net margin of -146.93%. Company Net Margins Return on Equity Return on Assets IMMURONN/A N/A N/A Scilex -146.93%N/A -82.65% SummaryScilex beats IMMURON on 7 of the 12 factors compared between the two stocks. Get IMMURON News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricIMMURONMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.38M$66.29M$5.53B$9.05BDividend YieldN/AN/A5.24%4.03%P/E RatioN/AN/A27.5020.21Price / Sales3.30N/A421.02118.64Price / CashN/AN/A36.8958.07Price / Book1.240.958.045.67Net Income-$4.55M-$26.57M$3.18B$249.13M IMMURON Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNIMMURON1.3224 of 5 stars$1.81-9.5%$5.00+176.2%-10.4%$10.38M$3.21M0.00N/ASCLXScilex1.7634 of 5 stars$5.89-2.6%$455.00+7,625.0%-90.5%$42.06M$56.59M-0.2080GRCEGrace Therapeutics1.8113 of 5 stars$2.97flat$12.00+304.0%N/A$41.07MN/A-3.34N/AGap DownSTTKShattuck Labs2.8809 of 5 stars$0.79-7.3%$7.50+847.2%-77.4%$40.89M$5.72M-0.57100Gap UpANVSAnnovis Bio1.6662 of 5 stars$2.18+6.3%$30.25+1,287.6%-70.5%$39.95MN/A-1.013PLURPluri3.6127 of 5 stars$4.95-2.8%$12.00+142.4%+2.1%$39.87M$330K-0.90150News CoveragePositive NewsInsider TradeMDCXMedicus Pharma2.0729 of 5 stars$2.99+3.1%$23.50+686.0%N/A$39.36MN/A-2.58N/AAnalyst ForecastGap UpPEPGPepGen2.959 of 5 stars$1.11-3.5%$7.67+590.7%-92.7%$37.63MN/A-0.3530AKTXAkari Therapeutics1.5648 of 5 stars$1.17+0.9%N/A-62.9%$37.30MN/A0.009XCURExicure1.9811 of 5 stars$7.04+19.5%N/A+1,941.3%$37.21M$500K-1.8450Earnings ReportHigh Trading VolumeRADXRadiopharm TheranosticsN/A$4.64-1.7%$12.00+158.6%N/A$37.20MN/A0.00N/APositive News Related Companies and Tools Related Companies SCLX Competitors GRCE Competitors STTK Competitors ANVS Competitors PLUR Competitors MDCX Competitors PEPG Competitors AKTX Competitors XCUR Competitors RADX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMMURON Please log in to your account or sign up in order to add this asset to your watchlist. Share IMMURON With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
